In line with this, we recently found that shRNA- and CRISPR/Cas9-mediated loss of SETD2 led to differentiation, enhanced DNA damage and apoptosis of acute myeloid leukemia (AML) cells harboring MLL-fusions in vitro and in vivo [30]. Here, KMT2A is linked to acute myeloid leukemia.